← All trials
NCT01129193
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 4, 2010
- Primary completion
- Jan 7, 2017
- Completion date
- Dec 31, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 44
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Ohio State UniversityLead sponsor
- Ohio State UniversityOverall official - principal investigator
- Ohio State UniversitySponsor investigator
- National Cancer Institute (NCI)Collaborator
- Arno TherapeuticsCollaborator
Drugs studied
Indications studied
- Burkitt Lymphoma
- Hodgkin Disease
- Lymphoma
- Lymphoma, Follicular
- Lymphoma, Non-Hodgkin
- Lymphomatoid Granulomatosis
- Waldenstrom Macroglobulinemia
- Multiple Myeloma
- Sezary Syndrome
- Testicular Neoplasms
- Transplantation
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia-Lymphoma, Adult T-Cell
- Leukemia, Prolymphocytic
- Lymphoma, T-Cell
- Lymphoma, Large-Cell, Immunoblastic
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, T-Cell, Peripheral
- Lymphoma, Large-Cell, Anaplastic
- Lymphoma, B-Cell, Marginal Zone
- Lymphoma, Mantle-Cell
- Lymphoma, Primary Cutaneous Anaplastic Large Cell
- Intraocular Lymphoma
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.